PI
SGMO

PEAK6 Investments’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

PEAK6 Investments’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-9,937
Closed -$17.5K – 4618
2023
Q1 		$17.5K Buy
+9,937
New +$28.4K ﹤0.01% 3907

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PEAK6 Investments's SGMO Position: Q2 2023 in Review

PEAK6 Investments sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2023, closing a stake of 9,937 shares — an estimated $17.5K sold.

PEAK6 Investments first reported a position in SGMO in Q1 2023 and held it in 1 quarter. The position peaked at $17.5K in Q1 2023. 152 funds tracked by Wall St. Rank hold SGMO as of Q2 2023.

  • PEAK6 Investments reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2023 after selling out during the quarter.
  • PEAK6 Investments sold 9,937 SANGAMO THERAPEUTICS INC shares in Q2 2023, an estimated $17.5K.
  • PEAK6 Investments first reported a position in SANGAMO THERAPEUTICS INC in Q1 2023 and held it in 1 quarter.
  • PEAK6 Investments's SANGAMO THERAPEUTICS INC position peaked at $17.5K in Q1 2023.
  • 152 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2023.

Based on PEAK6 Investments's 13F filing for Q2 2023, filed 11 Aug 2023.